![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
PHARMACOKINETIC INTERACTIONS BETWEEN THE HCV PROTEASE INHIBITOR BOCEPREVIR AND SIROLIMUS IN HEALTHY SUBJECTS
|
|
|
Reported by Jules Levin
EASL 2013 April 24-28 2013 Amsterdam
Ellen GJ Hulskotte1, Hwa-Ping Feng2, Fengjuan Xuan2, Wen Hong Lin2, Yali Zhu2, Scott Rasmussen3, Joan R Butterton2
1Merck Sharp & Dohme Corp., Oss, The Netherlands; 2Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA; 3Celerion, Lincoln, NE, USA
![EASL1.gif](../images/050613/050613-3/EASL1.gif)
![EASL2.gif](../images/050613/050613-3/EASL2.gif)
![EASL3.gif](../images/050613/050613-3/EASL3.gif)
![EASL4.gif](../images/050613/050613-3/EASL4.gif)
![EASL5.gif](../images/050613/050613-3/EASL5.gif)
![EASL6.gif](../images/050613/050613-3/EASL6.gif)
![EASL7.gif](../images/050613/050613-3/EASL7.gif)
![EASL8.gif](../images/050613/050613-3/EASL8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|